WO 2004/089938 A1

Title: A NOVEL CRYSTALLINE FORM OF IRBESARTAN

Abstract: The present invention relates to a novel crystalline form of irbesartan, to process for its preparation and a pharmaceutical composition containing it.
A NOVEL CRYSTALLINE FORM OF IRBESARTAN

FIELD OF THE INVENTION

The present invention relates to a novel crystalline form of irbesartan, to process for its preparation and a pharmaceutical composition containing it.

BACKGROUND OF THE INVENTION

Irbesartan or 2-Butyl-3-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-ene-4-one, which has the formula (1):

![Chemical Structure]

is a powerful angiotensin II receptor antagonist.

US 5,629,331 describes two crystalline forms of irbesartan (form A, B).

It has now been found that irbesartan can be prepared in a novel crystalline form (form C). The novel crystalline form is at least as stable as form A or form B and is not spontaneously converted to the previously known forms. The novel form is found to be suitable for pharmaceutical preparations.

The object of the present invention is to provide a stable novel crystalline form of irbesartan, a process for preparing it and a pharmaceutical composition containing it.

DETAILED DESCRIPTION OF THE INVENTION

According to one aspect of the present invention, there is provided a novel crystalline form of irbesartan, designated as form C, characterized by an x-ray powder diffraction pattern having peaks expressed as 2θ at about 8.3, 8.7,
10.1, 11.8, 15.0, 15.5, 16.4, 16.8, 17.5, 18.3, 19.1, 20.3, 21.1, 21.7, 23.6, 25.1, 25.5, 26.4, 26.8, 27.2, 28.1, 29.0 and 29.4 degrees. Figure 1 shows typical form C x-ray powder diffraction spectrum.

According to another aspect of the present invention, there is provided a process for preparation of the form C of irbesartan. Thus, irbesartan is mixed with a suitable solvent and irbesartan form C is isolated from the mixture. Preferably, the mixture of irbesartan and a suitable solvent is heated to reflux and the contents are filtered at about 5°C to 25°C. The suitable solvent is tetrahydrofuran or 1,4-dioxane; or a mixture thereof. Suitable solvent mixed with any other solvent/s like water may be used as long as irbesartan form C can be isolated from the solvent mixture. Previously known form of irbesartan or irbesartan prepared by a known method may be used in the process.

According to another aspect of the present invention there is provided a pharmaceutical composition comprising irbesartan form C. Irbesartan form C may be formulated in a form suitable for oral administration or injection.

**BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 is a x-ray powder diffraction spectrum of irbesartan form C. X-Ray powder diffraction spectrum was measured on a Siemens D5000 x-ray powder diffractometer having a copper-Kα radiation.

The following examples are given for the purpose of illustrating the present invention and should not be considered as limitations on the scope or spirit of the invention.

**Example 1**

Irbesartan (5.0 gm, obtained by the process described in example 5 of US 5,270,317) is mixed with tetrahydrofuran (350 ml), heated to reflux and maintained under reflux temperature for 30 minutes. The contents are cooled to 10°C. The separated crystals are collected by filtration to give 4.2 gm irbesartan form C.

**Example 2**

Example 1 is repeated using irbesartan form A for irbesartan to give irbesartan form C.
Example 3

Example 1 is repeated using irbesartan form B for irbesartan to give irbesartan form C.

Example 4

The mixture of Irbesartan (5.0 gm, obtained by process described in example 5 of US 5,270,317) and 1.4-dioxane (100 ml) is stirred for 5 hours at 20° C to 25° C. The solid is collected by filtration to give 4.7 gm irbesaratan form C.

Example 5

Irbesartan (5.0 gm, obtained by process described in example 5 of US 5,270,317) is added to a mixture of tetrahydrofuran (320 ml) and water (3 ml). The contents are heated to reflux, maintained under reflux temperature for 30 minutes and then cooled to 10° C. The separated crystals are collected by filtration to give 3.8 gm irbesaratan form C.
We claim:


2. A crystalline irbesartan form C of claim 1, further characterized by an x-ray powder diffraction pattern as in figure 1.

3. A process for preparation of irbesartan form C of claim 1, comprising the steps of:
   a) mixing irbesartan and tetrahydrofuran or 1,4-dioxane; and
   b) isolating irbesartan form C from the mixture.

4. A process according to claim 3, wherein irbesartan is mixed with tetrahydrofuran.

5. A process according to claim 3, wherein irbesartan is mixed with 1,4-dioxane.

6. A pharmaceutical composition comprising the crystalline irbesartan form C of claim 1 and a pharmaceutically acceptable carrier.
fig. 1/1

- Diagram showing a graph with the following axes:
  - X-axis: 2-Theta - Scale
  - Y-axis: Lin (Counts)
### INTERNATIONAL SEARCH REPORT

**PCT/IN 03/00146-0**

#### CLASSIFICATION OF SUBJECT MATTER

**IPC**: C07D 403/10

According to International Patent Classification (IPC) or to both national classification and IPC.

#### FIELDS SEARCHED

**IPC**: C07D 403/10

Minimum documentation searched (classification system followed by classification symbols).

**Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched**

Electronic database consulted during the international search (name of data base and, where practicable, search terms used):

STN Karlsruhe: CAS: CAPLUS and REGISTRY databases, EPOQUE: EPODOC

#### DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>D,A</td>
<td>US 5629331 A (CARON ET AL.) 13 May 1997 (13.05.97) the whole document.</td>
<td>1-6</td>
</tr>
<tr>
<td>A</td>
<td>EP 0420237 A1 (ESAI CO., LTD) 3 April 1991 (03.04.91) examples 2,3.</td>
<td>1-6</td>
</tr>
<tr>
<td>A</td>
<td>EP 0475898 A1 (CIBA-GEIGY AG) 18 March 1992 (18.03.92) example 9.</td>
<td>1-6</td>
</tr>
</tbody>
</table>

#### Date of the actual completion of the international search


#### Date of mailing of the international search report

10 February 2004 (10.02.2004)

Name and mailing adress of the ISA/AT

Austrian Patent Office

Dresdner Straße 87, A-1200 Vienna

Facsimile No. 1/53424/535

Authorized officer

SLABY S.

Telephone No. 1/53424/348

Form PCT/ISA/210 (second sheet) (July 1998)
## INTERNATIONAL SEARCH REPORT

### Information on patent family members

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP A 420237</td>
<td></td>
<td>NO A 904202</td>
<td>1991-04-22</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IS A 203324</td>
<td>1991-04-13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SE A 2007336</td>
<td>1991-10-30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RU A 55367</td>
<td>1991-05-28</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR B 9300168</td>
<td>1991-02-11</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ A 235449</td>
<td>1991-03-26</td>
</tr>
<tr>
<td>EP A 475898</td>
<td></td>
<td>IE A 913165</td>
<td>1992-03-11</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SE A 9107143</td>
<td>1992-04-29</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RU A 913129</td>
<td>1992-04-28</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO A 913542</td>
<td>1992-03-11</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT A 98903</td>
<td>1992-07-31</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FI A 914228</td>
<td>1992-03-11</td>
</tr>
<tr>
<td>US A 5629331</td>
<td></td>
<td>CY A 2277</td>
<td>2003-07-04</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GR T 3035503T</td>
<td>2001-06-29</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HK A 10051335</td>
<td>2001-08-17</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CZ B 288629</td>
<td>2001-08-15</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CZ B 288624</td>
<td>2001-08-15</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT T 708103T</td>
<td>2001-06-29</td>
</tr>
</tbody>
</table>